Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Evaluating the Cytotoxic Potential of Rifamycin-Loaded Liposomes in 2D and 3D Cancer Models

Nina Filipczak – Post Doc, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University; Satya Siva Kishan Yalamarty – PhD, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University; Priscila Mazzola – Professor, Faculty of Pharmaceutical Sciences, University of Campinas; Vladimir Torchilin – Professor, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University

    Poster Presenter(s)

  • Janaína A. Ataide, PhD

    Profa. Dra.
    School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo (FCFRP/USP)
    Ribeirão Preto, Sao Paulo, Brazil

Introduction:

Cancer is a significant global health burden, demanding new therapeutic strategies (1). The scientific community continuously seeks alternatives, from new drugs to novel delivery systems. Rifamycin, an antibiotic that inhibits RNA synthesis, presents potential as a cytotoxic agent (2). Liposomes, as well-established and biocompatible drug delivery platforms, can incorporate diverse drugs. Thus, our goal was to investigate rifamycin cytotoxic activity towards cancer cell lines in 2D and 3D models, using liposomes as delivery system.

Learning Objectives:

  • Describe the physicochemical stability and biocompatibility of rifamycin-loaded liposomes
  • Explain the time-dependent cytotoxic effects of liposomal rifamycin in 2D and 3D cancer cell models
  • Evaluate the advantages of liposomal drug delivery in improving rifamycin performance in complex tumor models